Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. is dated March 26, 2020, and pertains to the month of March 2020. The document serves as a notice of the Company's Annual General Meeting of Shareholders scheduled for May 4, 2020, in Tel Aviv, Israel. The filing incorporates the notice by reference into various Registration Statements on Forms S-8 and F-3.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document notes that shareholders will have an opportunity to review financial statements for the fiscal year ended December 31, 2019, at the upcoming meeting, but these figures are not included in this specific notice.
Material Changes
No material financial changes versus a prior comparable period are detailed in this filing. The document focuses on corporate governance actions and agenda items for the Annual General Meeting rather than operational or financial performance updates.
Guidance, Outlook, and Management Commentary
The Board of Directors recommends that shareholders vote "FOR" all proposals listed in the notice. Key agenda items include:
- Appointment of Kesselman & Kesselman as auditors for 2020.
- Re-election and election of directors, including Mr. Rick D. Scruggs, Dr. Shmuel Cabilly, Mr. Giuseppe Cipriano, and Mr. Nicolas Weinstein.
- Approval of Dror Ben-Asher to serve as Chairman of the Board and Chief Executive Officer.
- Amendments to the Compensation Policy and the Amended and Restated Award Plan (2010).
- Grants, extensions, and repricing of options to purchase American Depository Shares (ADSs) for directors and Mr. Dror Ben-Asher.
- Approval of an increase in the Company's authorized share capital.
The filing states the Company is currently unaware of any other matters that may be raised at the General Meeting.
Key Facts for Investor Verification
- Verify the outcome of the vote on the repricing of options for directors and Mr. Dror Ben-Asher, as this may impact dilution.
- Confirm the final financial statements for the fiscal year ended December 31, 2019, which are referenced for review but not included in this text.
- Monitor the approval of the increase in authorized share capital.
- Note the record date for voting eligibility is April 1, 2020.